About MOG‑AD

Understanding your condition

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG‑AD) is a rare inflammatory condition that affects the central nervous system. It is thought to be caused by autoantibodies, which are antibodies that mistakenly target healthy proteins in the body instead of harmful germs or viruses.

In MOG‑AD, these antibodies attack myelin oligodendrocyte glycoprotein (MOG), a protein found in the myelin, causing inflammation (or swelling) and damage.

The regions in the central nervous system usually affected in MOG‑AD are:

The optic nerves
(nerves involved in vision)

The spinal cord

The brain

The cosMOG study will work to find out if an investigational drug can prolong the time between relapses of inflammation.

About the cosMOG study

The cosMOG study aims to understand how well-tolerated and effective an investigational drug called rozanolixizumab is in people with MOG‑AD. The investigational drug will be given weekly as an infusion under the skin.

With no approved treatment options for MOG‑AD, we understand that your treatment journey may not have been an easy one. Clinical research studies, also called clinical trials, are a necessary and vital step toward understanding rare diseases such as MOG‑AD and how to treat them.

With your help, the cosMOG study will evaluate if an investigational drug can prolong the time between relapses for people with this condition.

Learn more about this study

Are you eligible?

You may be eligible to take part in the cosMOG study if you (among other things):

  • Are between 18 and 89 years old
  • Have relapsing MOG‑AD with at least one relapse in the last 12 months
  • Have at least one of the following:
  • Optic neuritis
  • Transverse myelitis
  • Acute disseminated encephalomyelitis (ADEM) or MOG‑AD encephalitis
Find a study site near you
null

This page is for healthcare providers only.

Are you a healthcare provider?

Yes

You are about to leave cosmogstudy.com. You will be redirected to outbound url.
Do you want to continue?

Yes

The content you are trying to access is no longer available.

Share

Copy page link

Send from your email account

Navigate to default email client